Abstract:Induced pluripotent stem cell (iPSC) therapies offer a promising path for patient-specific regenerative medicine. However, tumor formation from residual undifferentiated iPSC or transformation of iPSC or their derivatives is a risk. Inclusion of a suicide gene is one approach to risk mitigation. We introduced a dimerizable-"inducible caspase-9" (iCasp9) suicide gene into mouse iPSC (miPSC) and rhesus iPSC (RhiPSC) via a lentivirus, driving expression from either a cytomegalovirus (CMV), elongation factor-1 α (EF1α) or pluripotency-specific EOS-C(3+) promoter. Exposure of the iPSC to the synthetic chemical dimerizer, AP1903, in vitro induced effective apoptosis in EF1α-iCasp9-expressing (EF1α)-iPSC, with less effective killing of EOS-C(3+)-iPSC and CMV-iPSC, proportional to transgene expression in these cells. AP1903 treatment of EF1α-iCasp9 miPSC in vitro delayed or prevented teratomas. AP1903 administration following subcutaneous or intravenous delivery of EF1α-iPSC resulted in delayed teratoma progression but did not ablate tumors. EF1α-iCasp9 expression was downregulated during in vitro and in vivo differentiation due to DNA methylation at CpG islands within the promoter, and methylation, and thus decreased expression, could be reversed by 5-azacytidine treatment. The level and stability of suicide gene expression will be important for the development of suicide gene strategies in iPSC regenerative medicine.

CRISPR/Cas9 Mediated Generation of a Ipsc Line EHTJUi005-A-1 with Homozygous Knockout of the SUV39H1 Gene.

Generation of a Lamin A/C Knockout Human Induced Pluripotent Stem Cell Line (Zjulli007-A) Via CRISPR/Cas9

Generation of a TRPV1 Knockout Human Pluripotent Stem Cell Line (Wae009-a-u) Using CRISPR/Cas9.

Enhancement of Xrcc1-mediated Base Excision Repair Improves the Genetic Stability and Pluripotency of Ipscs

Generation of an Induced Pluripotent Stem Cell Line (Zjulli003-A) from a Hypertrophic Cardiomyopathy Patient Carrying MYH7/c.4384G > A Mutation

Establishment of an Induced Pluripotent Stem Cell Line (Zjulli004-A) from a Hypertrophic Cardiomyopathy Patient Carrying MYBPC3/c.3764C>A Mutation

Generation of a Homozygous CRISPR/Cas9-mediated Knockout Human Ipsc Line for PTCH1 Gene.

Generation of a homozygous (MCRIi031-A-3) WT1 knockout human iPSC line

Generation of heterozygous (MCRIi031-A-1) and homozygous (MCRIi031-A-2) SOX9 knockout human iPSC lines

Generation of a ISL1 homozygous knockout stem cell line (WAe009-A-1G) by episomal vector-based CRISPR/Cas9 system

Generation of a Human Charcot-Marie-Tooth Disease Type 1B (CMT1B) Ipsc Line, ZJUCHi001-A, with a Mutation of C.292c>t in MPZ.

Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins.

An episomal vector-based CRISPR/Cas9 system for highly efficient gene knockout in human pluripotent stem cells

Generation of a homozygous TIGIT gene knockout (TIGIT-/-) human iPSC line (MUSIi001-A-3) using CRISPR/Cas9 system

Engineering Human Stem Cell Lines with Inducible Gene Knockout Using CRISPR/Cas9

Generation of a Human Induced Pluripotent Stem Cell Line from a Female Patient Carrying LZTR1 Gene Mutation

Generation of a PPM1A -deficient human induced pluripotent stem cell line using CRISPR-Cas9 technology

Using Gene Editing to Establish a Safeguard System for Pluripotent Stem-Cell-Based Therapies.

Derivation of Induced Pluripotent Stem Cells Line (RCPCMi009-A-1) with Knockout of the UBE2A Gene by CRISPR/Cas9 Genome Editing

Development of an inducible caspase-9 safety switch for pluripotent stem cell–based therapies

Generation of a Well-Characterized Homozygous Chromodomain-Helicase-DNA-Binding Protein 4G1003D Mutant hESC Line Using CRISPR/eCas9 (ULIEGEe001-A-1)